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The continuing emergence of multi-drug resistant pathogens has sparked an interest
in seeking alternative therapeutic options. Antimicrobial combinatorial therapy is one
such avenue. A number of studies have been conducted, involving combinations of
bacteriocins with other antimicrobials, to circumvent the development of antimicrobial
resistance and/or increase antimicrobial potency. Such bacteriocin-antimicrobial
combinations could have tremendous value, in terms of reducing the likelihood
of resistance development due to the involvement of two distinct mechanisms of
antimicrobial action. Furthermore, antimicrobial synergistic interactions may also have
potential financial implications in terms of decreasing the costs of treatment by reducing
the concentration of an expensive antimicrobial and utilizing it in combination with an
inexpensive one. In addition, combinatorial therapies with bacteriocins can broaden
antimicrobial spectra and/or result in a reduction in the concentration of an antibiotic
required for effective treatments to the extent that potentially toxic or adverse side effects
can be reduced or eliminated. Here, we review studies in which bacteriocins were found
to be effective in combination with other antimicrobials, with a view to targeting clinical
and/or food-borne pathogens. Furthermore, we discuss some of the bottlenecks which
are currently hindering the development of bacteriocins as viable therapeutic options,
as well as addressing the need to exercise caution when attempting to predict clinical
outcomes of bacteriocin-antimicrobial combinations.
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INTRODUCTION
The recent increase in the number of cases of antibiotic resistance has encouraged scientists
to reassess alternative therapeutic options (Michael et al., 2014; Holmes et al., 2016). The rate
of antibiotic resistance is worrying since progress in the discovery of novel antibiotics with
different modes of action has slowed significantly. There are some exceptions, such as the relatively
recent discovery of teixobactin, which exhibits activity against Gram positive pathogens including
methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae and mycobacteria,
and which has a distinct mechanism of action involving the inhibition of peptidoglycan synthesis
(Ling et al., 2015). Encouragingly, teixobactin proved to be effective in mouse trials in decreasing
the load of S. pneumoniae and MRSA. Furthermore, S. aureus and M. tuberculosis isolates
displaying resistance to teixobactin could not be isolated under laboratory conditions (Ling
et al., 2015). In general, however, the widespread discovery of novel antibiotics remains largely
uncommon (Cooper and Shlaes, 2011).
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One option to compensate for the dearth of novel antibiotics
is to introduce bacteriocins as therapeutic options in clinical
settings. Bacteriocins are ribosomally-synthesized antimicrobial
peptides produced by bacteria and can exhibit narrow spectra
of activity (targeting members of the same species), whereas
others display broader activity spectra (targeting other species
and genera) (Cotter et al., 2013). Bacteriocins are broadly
classified into class I (post-translationally modified) and class
II (unmodified) groups. The most extensively studied subclass
of bacteriocins is the lantibiotics, which includes nisin, lacticin
3147, mersacidin, lacticin 481 and staphylococcin C55, amongst
others (Brötz et al., 1995; McAuliffe et al., 1998; Navaratna et al.,
1998; Xie et al., 2004; Field et al., 2008). Several lantibiotics
exhibit potent activity against clinically relevant and food-borne
pathogens (Mota-Meira et al., 2000; Kruszewska et al., 2004;
Cotter et al., 2005, 2013; Rea et al., 2007; de Kwaadsteniet
et al., 2009; Piper et al., 2009; Jabes et al., 2011; Field et al.,
2012, 2015). Significantly, some lantibiotics have been shown
to possess activity against antibiotic-resistant targets such as
vancomycin-resistant enterococci (VRE) and MRSA (Chatterjee
et al., 1992; Kruszewska et al., 2004; Piper et al., 2009). In a
number of instances, the receptor for the lantibiotic subclass
of bacteriocins is the peptidoglycan precursor lipid II, which
is also the binding site for vancomycin, albeit at a different
site within the precursor (Breukink and de Kruijff, 2006). The
class II bacteriocins, which are unmodified or cyclic in nature,
are further divided into class IIa-IIe (Cotter et al., 2013). The
class IIa subgroup of bacteriocins generally have strong activity
against the food-borne pathogen, Listeria monocytogenes (Pucci
et al., 1988; Eijsink et al., 1998; Gravesen et al., 2002; Héchard
and Sahl, 2002; Dabour et al., 2009). In contrast to class I
bacteriocins, several class IIa bacteriocins bind the mannose
phosphotransferase receptor (Man-PTS; Oppegård et al., 2007).
Overall, bacteriocins exhibit strong activity against their target
strains, often in the nanomolar range, rendering them more
potent than their antibiotic counterparts in certain cases (Mathur
et al., 2013; Ming et al., 2015). Thus, bacteriocins on their own
have potential for use in clinical applications.
However, perhaps an even better option is to combine
bacteriocins with other existing antibiotics/antimicrobials. It is
plausible that using antimicrobials that function synergistically
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; VRE,
vancomycin-resistant enterococci; Man-PTS; mannose phosphotransferase;
FIC, fractional inhibitory concentration; MCBT, multiple combination
bactericidal test; PBP, penicillin binding protein; MIC, minimum inhibitory
concentration; MBC, minimum bactericidal concentration; TEM, transmission
electron microscopy; CDAD, Clostridium difficile-associated diarrhea; SAM,
S-adenosylmethionine; LAE, lauramide arginine ethyl ester; ATCC, American
Type Culture Collection; XTT, 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide; MSSA, methicillin-sensitive Staphylococcus
aureus; CFU, colony forming units; CLSM, confocal laser scanning microscopy;
PHMG, polyhexamethylene guanidinium chloride; MTAD, mixture of tetracycline
isonomer, acid and detergent; ATP, adenosine triphosphate; GTE, green tea
extract; GSE, grape seed extract; EDTA, ethylene diamine tetraacetic acid;
PHBME, p-hydroxybenzoic methylester acid; CFS, cell-free supernatants; DPC,
Dairy Products Culture Collection; SEM, scanning electron microscopy; NPN,
1-N-phenylnapthylamine; DNA, deoxyribonucleic acid; RNA, ribonucleic acid;
NONMEM, non-linear mixed effects modeling tool; CDI; C. difficile infection.
with bacteriocinsmay expedite each other’s killing effects, thereby
possibly reducing the likelihood of resistance development to
either the bacteriocin or the antimicrobial stressor. Furthermore,
combinations of bacteriocins with antibiotics can decrease the
concentration of antibiotics required to kill a target pathogen,
thereby diminishing the likelihood of adverse side effects
associated with the antibiotic. An example of such undesirable
effects is the nephrotoxicity associated with the polymyxin group
of antibiotics (Mendes et al., 2009; Abdelraouf et al., 2012).
Synergistic combinations of bacteriocins with antibiotics can
also reduce the financial burden associated with the synthesis
and administration of the more expensive antibiotics. Finally,
successful synergistic interactions between bacteriocins and other
antimicrobials can broaden the spectrum of activity, which may
be useful in treating clinical infections of unknown etiology.
A variety of different methods assessing antimicrobial synergy
in laboratory conditions have been described in the literature.
Examples of such tests include the broth-based checkerboard
assay, as well as agar-based screens such as E-tests (bioMérieux)
to evaluate synergy (Orhan et al., 2005; Tsuji and Rybak, 2006;
Foweraker et al., 2009; Sopirala et al., 2010; Soltani et al., 2012).
However, there is a general consensus that agar-based screens
are relatively crude compared to the more accurate broth-based
methods. The checkerboard method permits the determination
of the fractional inhibitory concentration (FIC) index. Although
some researchers disagree about the interpretation of results
obtained with checkerboard assays, there appear to be five
different effects on which the majority of researchers have
reached a consensus. These five effects are (i) full synergy
(FIC ≤ 0.5), (ii) partial synergy (0.5 ≤ FIC ≤ 0.75), (iii)
additive effects (0.75 ≤ FIC ≤ 1.0), (iv) indifferent effects
(1.0 ≤ FIC ≤ 2.0) and (v) antagonistic effects (FIC ≥ 2.0)
(Bacon et al., 1991; Orhan et al., 2005). The main disadvantage
of the checkerboard assay is that it can only examine two
antimicrobials at a time. On the other hand, an assay known
as the multiple combination bactericidal test (MCBT) has the
potential to evaluate combinations of up to four antimicrobials
concurrently. While checkerboard assays evaluate different
antimicrobial concentrations,MCBT assays only evaluate defined
set concentrations of antimicrobials. MCBT assays are based on
the premise that 99.9% of the bacterial population is killed after
24 h. Synergy can also be assessed by combining antimicrobials
together and conducting time-kill assays, whereby samples are
taken at defined time points to evaluate the effects of two or
more antimicrobials together (Doern, 2014). Finally, it must be
emphasized that there can be variations in terms of the types
of interactions obtained between different methods. Variations
frequently observed between different methods can be ascribed
to slight differences in the end-points used in the assays. It should
also be noted that in vitro results do not necessarily predict the
success of different combinations in vivo.
In this review, we outline a selection of studies conducted
whereby bacteriocins were combined successfully with
other bacteriocins, antibiotics, phage lysins and other
antimicrobials/stressors such as naturally-derived plant essential
oils, with a view to targeting clinical/veterinary pathogens,
pathogens involved in biofilms, and food-borne pathogens.
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EFFECTS OF ANTIMICROBIAL
COMBINATIONS INVOLVING
BACTERIOCINS AGAINST CLINICAL AND
VETERINARY PATHOGENS
Lantibiotics in Combination with
Antibiotics against Clinical and Veterinary
Pathogens
The lantibiotics are the most extensively studied group of
bacteriocins (Cotter et al., 2013). These bacteriocins are post-
translationally modified antimicrobial peptides, characterized
by the presence of unusual amino acids, and their structure
involves lanthionine and β-methyl lanthionine intramolecular
bridges. During the formation of these intramolecular bridges,
serine and threonine residues are dehydrated to dehydroalanine
and dehydrobutyrine respectively (Cotter et al., 2013). In one
study, the most thoroughly investigated lantibiotic, nisin (at
concentrations ranging from 1.5 to 16 µg/ml), was combined
with the glycolipodepsipeptide ramoplanin (at concentrations
ranging from 0.38 to 1.5µg/ml), both of which target lipid II, and
the combination resulted in synergistic interactions against 14
out of 20MRSA strains assessed (Brumfitt et al., 2002). Resistance
tomethicillin in S. aureus is a significant problem and is mediated
by the expression of PBP2a (penicillin binding protein 2a)
instead of, or in addition to, the regular PBP (Hackbarth et al.,
1995; Stapleton and Taylor, 2002; Chambers and Deleo, 2009).
Furthermore, β-lactamase expression is also known to contribute
to resistance to methicillin amongst S. aureus strains (Montanari
et al., 1996), rendering such MRSA strains amongst the most
challenging pathogens to target in clinical settings. In contrast
to the effective nisin-rampolanin interactions however, the study
by Brumfitt et al., showed that a combination of nisin with 3–
12 µg/ml chloramphenicol (which inhibits protein synthesis in
bacteria) yielded antagonistic effects against these MRSA strains
(Brumfitt et al., 2002).
Enterococcus faecalis is another nosocomial pathogen and is
an etiological agent of endocarditis, urinary tract infections and
other systemic infections, and has exhibited resistance to several
groups of antibiotics including aminoglycosides, daptomycin,
quinolones, macrolides, rifampicin and β-lactams, amongst
others (Murray, 1990; Johnston and Jaykus, 2004; Flores-Mireles
et al., 2015). A study by Tong et al., demonstrated that the
presence of 200 U/ml nisin led to a reduction in minimum
inhibitory concentration (MIC) and minimum bactericidal
concentration (MBC) values of 18 different antibiotics against
E. faecalis. The combinations of 200 U/ml nisin with 1–16 µg/ml
chloramphenicol or with 2 µg/ml penicillin were especially
effective, with statistically significant improvements in MIC
values in the presence of nisin. Synergistic interactions between
nisin in combination with either penicillin or chloramphenicol
against three E. faecalis strains were also apparent with
checkerboard assays. In addition, transmission electron
microscopy (TEM) demonstrated that these combinations were
highly effective at destroying E. faecalis cells (Tong et al., 2014a).
In another study, the lipid II-binding lantibiotic, actagardine,
was combined with the antibiotics metronidazole, vancomycin
and ramoplanin against several Clostridium difficile isolates
(Mathur et al., 2013). C. difficile is primarily a nosocomial
pathogen and is the causative agent of C. difficile-associated
diarrhea (CDAD), which often occurs due to perturbations of
the gut microbiota resulting from broad-spectrum antibiotics
(Rea et al., 2010; Leﬄer and Lamont, 2015). Interestingly, it
was revealed that actagardine in combination with ramoplanin
behaved in a partial synergistic/additive fashion against 61.5%
of the target C. difficile strains assessed in the relatively recent
study (Mathur et al., 2013). Actagardine-metronidazole and
actagardine-vancomycin combinations were also effective with
partial synergistic/additive effects obtained against 54% and 38%
of C. difficile strains respectively (Mathur et al., 2013).
With respect to veterinary pathogens, LeBel et al., reported
that nisin behaved in a synergistic manner when combined with
the β-lactams amoxicillin, penicillin or ceftiofur, and also when
combined with streptomycin or tetracycline against Streptococcus
suis (LeBel et al., 2013). Although S. suis is primarily a porcine
pathogen, it has also been described as a zoonotic pathogen with
transmission to humans possible (Hughes et al., 2009; Goyette-
Desjardins et al., 2014; Huong et al., 2014). The novel lantibiotic,
suicin 3908, was also shown to interact in an additive manner
with amoxicillin or penicillin against S. suis in a recent study
(Vaillancourt et al., 2015).
Sactibiotics and Other Groups of
Bacteriocins, in Combination with
Antimicrobials against Clinical Pathogens
The sactibiotics are a relatively newly-designated group of
bacteriocins, characterized by post-translational modifications
involving radical S-adenosyl methionine (SAM) methylases and
the presence of sulfur to α-carbon linkages in their structure
(Arnison et al., 2013; Mathur et al., 2015). In general, the
sactibiotics tend to be relatively hydrophobic in nature with
characteristic hairpin-shaped structures. The efficacy of the
sactibiotic, thuricin CD, was assessed in combination with
metronidazole, ramoplanin and vancomycin, with a view to
targeting C. difficile strains. It was revealed that thuricin CD
interacted in a partial synergistic manner when combined
with ramoplanin against 31% of the target strains tested
(Mathur et al., 2013). In contrast, combinations of thuricin
CD-vancomycin and thuricin CD-metronidazole resulted in
indifferent effects (1.0 ≤ FIC ≤ 2.0) against the majority of
C. difficile isolates tested in the study (Mathur et al., 2013).
Antimicrobial combination studies have also been conducted
with the sactibiotic subtilosin A against Gardnerella vaginalis.
This opportunistic pathogen is one of the predominant causative
agents of bacterial vaginosis (Catlin, 1992). It was determined
that subtilosin A exhibited Bliss synergy when combined
with clindamycin phosphate, metronidazole, ε-Poly-L-Lysine
(polylysine) and lauramide arginine ethyl ester (LAE) against
the pathogen (Cavera et al., 2015). Bliss synergy is based on the
principle that drug effects are outcomes of probabilistic processes
and assumes that drugs act independently in such a manner that
neither of them interferes with the other (different sites of action),
but each contributes to a common result (Tang et al., 2015).
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However, only subtilosin A-metronidazole and subtilosin A-
clindamycin combinations yielded synergistic effects against G.
vaginalis when FIC indices were evaluated (Cavera et al., 2015).
Subtilosin produced by Bacillus amyloliquefacienswas also shown
to exhibit synergistic activity with lauric arginate, ε-poly-L-lysine
and glycerol monolaurate against G. vaginalis in an earlier study
(Noll et al., 2012). Finally, a recent study demonstrated that
combinations of the class II bacteriocin, durancin 61A and the
broad-spectrum antimicrobial reuterin yielded FIC indices of 0.2
against C. difficile, indicating highly synergistic activity (Schaefer
et al., 2010; Hanchi et al., 2017). Interestingly, durancin 61A
combinations with vancomycin were also synergistic against
MRSA (S. aureus ATCC 700699) with FIC values of 0.3 obtained
(Hanchi et al., 2017).
With respect to the treatment of oral pathogens, one study
investigated the combination of the bacteriocin PsVP-10, a non-
lantibiotic displaying characteristics akin to class II bacteriocins,
with the antimicrobials triclosan and chlorhexidine in an effort
to target Streptococcus mutans and Streptococcus sobrinus (Lobos
et al., 2009). S. mutans is the predominant causative agent of
dental caries (Loesche, 1986; Metwalli et al., 2013), while S.
sobrinus has also been implicated in its causation, albeit to a lesser
extent than S. mutans (Conrads et al., 2014). Synergistic effects
were obtained when PsVP-10 was combined with chlorhexidine,
whereas partial synergistic/additive effects were apparent with
PsVP-10-triclosan combinations in the study by Lobos et al.
(2009). Candida albicans is the etiological agent of many
opportunistic yeast infections in the oral cavity as well as other
parts of the body and it is noteworthy that the class II bacteriocins
plantaricin E, F, J, andK have displayed activity againstC. albicans
when used in combination with several different antibiotics
(Sharma and Srivastava, 2014). This opportunistic pathogen
typically infects immunosuppressed individuals. Indeed, it is
frequently implicated in oro-pharyngeal thrush in AIDS patients
and can also be a causative agent of systemic infections such as
vaginitis (Kim and Sudbery, 2011). Thus, effective combinations
of therapeutics to target this pathogen are warranted.
Effective Bacteriocin-Antimicrobial
Combinations against Biofilms
Bacteria present in a biofilm are inherently more resistant
to antimicrobials than those present in a planktonic state
predominantly due to the complex polymeric matrix which
biofilms are composed of, and this matrix often impedes
penetration of the antimicrobial to the deepest strata of the
biofilm (Mah and O’Toole, 2001; Davies, 2003; Flemming
and Wingender, 2010). Thus, there is an increased emphasis
on trying to seek alternative therapeutic options and/or
effective antimicrobial combinations to target biofilms. A
recent study showed that nisin interacts synergistically with
several antibiotics and such combinations were effective against
Staphylococcus biofilms (Field et al., 2016a). In particular,
the bioengineered variant of nisin, M21V, in combination
with penicillin was effective at inhibiting biofilms of S.
aureus SA113. In contrast to SA113 biofilms however, M21V
was most effective in combination with chloramphenicol
against SA113 planktonic cells (Figure 1C). Furthermore,
another variant, nisin I4V, was reported to be highly effective
in conjunction with chloramphenicol against Staphylococcus
pseudintermedius DSM21284 biofilms in the same study,
while combinations of I4V with penicillin were particularly
potent against DSM21284 planktonic cells (Field et al., 2016a;
Figures 1B, 2). S. pseudintermedius is an opportunistic pathogen,
primarily affecting dogs (van Duijkeren et al., 2011) and an
outbreak of methicillin-resistant S. pseudintermedius in Finland
has been documented in recent years (Grönthal et al., 2014).
Significantly, a case of S. pseudintermedius in a human was also
described for the first time in 2006 (Van Hoovels et al., 2006).
While the use of the colorimetric XTT assay revealed that nisin
I4V-chloramphenicol combinations were effective at diminishing
the viability of the biofilms of a S. pseudintermedius strain in
the study by Field and co-workers, the authors found that there
was no synergy with nisin-vancomycin combinations against
Staphylococcus biofilms (Field et al., 2016a). Indeed, variations
with respect to the nature of interactions between nisin and
vancomycin when targeting MRSA or methicillin-sensitive S.
aureus (MSSA) have also been reported in previous studies
(Dosler and Gerceker, 2011, 2012). A separate study by Mataraci
and Dosler also investigated the potency of several antibiotics
combined with nisin against MRSA ATCC43300 biofilms and
it was determined that antibiotic-nisin combinations were
effective at preventing biofilm formation at 1x MIC. However,
biofilm-associated bacteria were highly resistant to antibiotics or
antibiotic combinations (Mataraci and Dosler, 2012). In another
study, it emerged that nisin in combination with ciprofloxacin
or daptomycin was effective against 24 h-old MRSA biofilms.
The combination elicited a reduction in MRSA CFU counts by
3 logs, whereas the individual antimicrobials were unable to
decrease the CFU to such an extent (Dosler and Mataraci, 2013).
A recent interesting study evaluated the activity of nisin and
lysostaphin against pre-formed biofilms of S. aureus involved
in bovine mastitis (Ceotto-Vigoder et al., 2016). After treatment
for 24 h with a combination of nisin and lysostaphin, the
biofilm pre-formed by all eight strains tested in the study was
reduced by >50%, as suggested by biofilm detachment from the
microtiter plates. Although no remarkable detachment could be
noticed by confocal laser scanning microscopy (CLSM) analysis
after a 4 h treatment, when the biofilm matrix of S. aureus
4181 was assayed for cell viability, most cells were shown
to be dead (Ceotto-Vigoder et al., 2016). In contrast to the
synergistic activity between nisin and lysostaphin, significantly
higher concentrations of lysostaphin used on its own, up
to 50-fold higher, were required to cause the same level of
biofilm detachment achieved by nisin-lysostaphin combinations.
A separate study evaluated the antimicrobial effects of the
class IIc bacteriocin enterocin AS-48 both independently and
in combination with several biocides against three MRSA and
three MSSA strains (Caballero Gómez et al., 2013). It was
determined that the anti-biofilm activity of the biocides triclosan,
benzalkonium chloride and polyhexamethylene guanidinium
chloride (PHMG) were highly effective in combination with 50
µg/ml of AS-48 (Caballero Gómez et al., 2013). Thus, these
combinations may prove to be useful therapeutic options for
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FIGURE 1 | Activity of nisin and bioengineered derivatives thereof, in combination with different antimicrobials against various pathogens: (A) Pseudomonas
aeruginosa PA-01 in the presence of nisin A (50 µg/ml) (orange diamond), colistin (0.75 µg/ml) (blue square), in combination (red diamond) and untreated (green
circle), (B) S. pseudintermedius DSM 21284 in the presence of nisin I4V peptide (0.932 µg/ml) (orange diamond) with penicillin (Pen) (0.8 µg/ml) (blue square), in
combination (red diamond), and untreated (green circle). (C) S. aureus SA113 in the presence of nisin V (3.0 µg/ml), (orange diamond), 1.5 µg/ml chloramphenicol
(Cm) (blue square), in combination (red diamond), and untreated (green circle) and (D) E. coli O157:H7 in the presence of nisin S29A (orange diamond), carvacrol
(200µg/ml) (blue square) and combinations of nisin S29A and carvacrol (red inverted triangle) and untreated (green circle). Adapted from Field et al. (2016a,b) and
Campion et al. (2017). Rights and Permissions have been obtained from Copyright Clearance Center’s RightsLink service.
MRSA. Finally, Tong and co-workers also reported the efficacy
of nisin in combination with chloramphenicol, ciprofloxacin or
penicillin at targeting biofilms of the nosocomial pathogen, E.
faecalis (Tong et al., 2014a).
With a specific goal of finding therapeutics against oral
biofilms, Tong and co-workers also examined the anti-
biofilm activities of the lantibiotic nisin, independently and in
combination with free amino acids against S. mutans biofilms.
The results of crystal violet biofilm assays indicated that mixtures
of either the L or D-enantiomers of Glu, Asp or Cys in
combination with nisin could ameliorate the potency of the
lantibiotic against biofilms of S. mutans (Tong et al., 2014b).
In an earlier study, the same group found that nisin interacted
synergistically with sodium fluoride against S. mutans biofilms,
in that the combination was more effective than sodium fluoride
used independently at inhibiting the formation of biofilms
at 4 and 16 h (Tong et al., 2011). The same investigators
also assessed the effect of adding nisin to the dental irrigant,
MTAD, and its anti-biofilm activity against oral E. faecalis
isolates. Importantly, it was found that nisin in combination with
doxycycline successfully inhibited E. faecalis biofilms whereas
MTAD on its own was ineffective against such biofilms (Tong
et al., 2013). E. faecalis, best known as a notorious nosocomial
pathogen causing systemic infections, is also implicated in
root canal infections. These successful combinations mentioned
above could be harnessed as effective antimicrobial combinations
against E. faecalis and S. mutans biofilms or as part of an
endodontic irrigant following root canal treatments to prevent
post-operative infections.
With respect to Gram negative organisms, a recent study
found that nisin was effective when used together with
polymyxins against Pseudomonas aeruginosa biofilms (Field
et al., 2016b). P. aeruginosa is an important opportunistic
pathogen and its biofilm-forming abilities contribute to its
pathogenicity (Gellatly and Hancock, 2013). It is particularly
common in lungs of patients with cystic fibrosis and thus
warrants further extensive research to target its biofilm-
forming and consequent pathogenic properties (Reen et al.,
2016). The study by Field and co-workers demonstrated that
decreased concentrations of polymyxins (either 0.5x MIC
or even 0.2x MIC) are required to prevent P. aeruginosa
PA-01 biofilm formation, when combined with 0.25x MIC
nisin. Combinations of 0.33x MIC of nisin with 0.5x MIC
of polymyxin were also effective against PA-01 planktonic
cells (Field et al., 2016b; Figure 1A). Nisin was also used
in combination with other antimicrobial agents used in the
clinic against planktonic cells of P. aeruginosa ATCC 27853,
as well as 40 other strains of P. aeruginosa in a separate
study (Giacometti et al., 1999). A synergistic interaction of
this nature can be hugely beneficial as it has the potential
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FIGURE 2 | Activity of nisin I4V in combination with chloramphenicol against
S. pseudintermedius DSM21284 biofilms: Viability of biofilms of
S. pseudintermedius DSM 21284 when (A) untreated, (B) treated with 1X MIC
chloramphenicol alone, (C) treated with 4X MIC nisin I4V peptide alone and
(D) 1X MIC chloramphenicol and 4X MIC nisin I4V peptide in combination as
evaluated by the colorimetric XTT assay and measured using a microtiter plate
reader (top) and Live/dead staining confocal images (bottom). Adapted from
Field et al. (2016a). Rights and Permissions have been obtained from
Copyright Clearance Center’s RightsLink service.
to attenuate the undesired nephrotoxicity associated with
polymyxins.
A recent study using the sactibiotic, subtilosin, in combination
with LAE was undertaken with a view to targeting G. vaginalis
biofilms (Algburi et al., 2015). A combination of two methods;
ATP viability assays and resazurin assays, were conducted to
show the efficacy of these combinations against biofilms of the
pathogen. Encouragingly, this combination of subtilosin-LAE
was ineffective against healthy vaginal Lactobacillus biofilms.
This highlights the specific nature of antimicrobial combinations
and such a combination could be harnessed as a targeted
therapeutic option against bacterial vaginosis. Furthermore,
bacteriocins can potentially be combined with agents that target
biofilms through non-microbiocidal means such as by altering
molecular pathways which are responsible for regulating biofilm
formation. Examples of such agents include thiazolidinone
derivatives and diterpenoids (Buommino et al., 2014).
A summary of studies involving bacteriocins in combination
with other stressors with a view to targeting clinical and
veterinary pathogens, as well as biofilms, is found in Tables 1, 2.
EFFECTS OF ANTIMICROBIAL
COMBINATIONS INVOLVING
BACTERIOCINS AGAINST FOOD-BORNE
PATHOGENS
With regards to the food industry, disease-causing and spoilage
organisms can have tremendous implications in terms of
morbidity/mortality, as well as financial implications. Several
persistent pathogens exist in food systems, both in planktonic
states as well as in biofilms. Furthermore, there is an emphasis
on attempting to replace chemically-derived antimicrobials in
food with more natural antimicrobials such as nisin and plant-
derived essential oils. The increase in the extent of global
food distribution, in conjunction with more frequent travel has
elicited an increase in the dissemination of food-borne diseases
and solutions are required to combat this trend (Hussain and
Dawson, 2013). While the use of chemical preservatives as well
as heat treatment have proven to be successful in the past in
limiting food-borne pathogens as part of the hurdle effect, such
treatments can have an impact on the organoleptic properties
of food. In addition, increasing pressure from consumers for
safe to eat food which is minimally processed has ignited an
interest in the development of effective natural antimicrobials or
antimicrobial combinations to control food-borne pathogens.
Combinations of Bacteriocins with
Essential Oils, Naturally-Derived
Compounds and Preservatives against
Gram Positive Food-Borne Pathogens
The lantibiotic nisin has been the subject of several antimicrobial
combination studies with a view to targeting food-borne
pathogens. Indeed, it has been utilized for decades as a food
preservative in more than 50 countries (Delves-Broughton,
1990). L. monocytogenes, the causative agent of listeriosis, is a
notorious food-borne pathogen, and can cause opportunistic
infections which can lead to meningitis and sepsis in severe cases
(Low and Donachie, 1997; Schuppler and Loessner, 2010). In
one study, it was found that 6,400 IU of nisin in combination
with a green tea extract (GTE) or in combination with a grape
seed extract (GSE) resulted in effective cell damage in a target
L. monocytogenes strain (Sivarooban et al., 2008). The purified
phenolic compounds present in GTE (0.02% epicatechin and
0.02% caffeic acid), as well as the pure phenolic compounds
present in GSE (0.02% catechin and 0.02% epicatechin) were
also used in the study (Sivarooban et al., 2008). When nisin
was combined with GTE or GSE compounds, a compromised
cell membrane and a condensed cytoplasm were apparent with
TEM. With a starting inoculum of 106 CFU/ml, the combination
of nisin with GSE resulted in Listeria levels which were
undetectable after 24 h of incubation, whereas the combination
of nisin and GTE led to a decrease in Listeria levels to a
mere 3.76 CFU/ml (Sivarooban et al., 2008). In another study,
it was shown that semi-purified preparations of nisin A and
a bioengineered derivative nisin V, combined effectively with
the essential oils carvacrol, thymol and trans-cinnamaldehyde
to inhibit L. monocytogenes in a validated food model system,
as well as in laboratory media. It was shown that a greatly
delayed lag phase was apparent during growth curves when nisin
V was combined with 0.02% of the above-mentioned essential
oils, compared to the nisin A equivalent (Field et al., 2015).
Additionally, in time-kill assays, a 2-log decrease in cell numbers
over and above that achieved by the nisin A combination
with carvacrol or cinnamaldehyde was observed against the
target L. monocytogenes EGDe, which was also maintained in
a number of food settings (Field et al., 2015). In a separate
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TABLE 1 | Bacteriocins in combination with other stressors against clinical and veterinary pathogens.
Bacteriocin Antimicrobial/Stressor Target Effect References
Nisin Ramoplanin or chloramphenicol MRSA Synergy with ramoplanin against 14/20 strains;
antagonism with chloramphenicol
Brumfitt et al., 2002
Polymyxin E or clarithromycin P. aeruginosa Synergy Giacometti et al., 1999
Amoxicillin, penicillin, streptomycin
ceftiofur, tetracycline
S. suis Synergy with every combination LeBel et al., 2013
Chloramphenicol or penicillin E. faecalis Synergy with the antibiotics Tong et al., 2014a
Actagardine Ramoplanin C. difficile Partial synergy/additive against 8/13 strains Mathur et al., 2013
Metronidazole C. difficile Partial synergy/additive against 7/13 strains Mathur et al., 2013
Vancomycin C. difficile Partial synergy/additive against 5/13 strains Mathur et al., 2013
Lacticin 3147 Polymyxin B or E E. faecium DO Indifference Draper et al., 2013
Polymyxin B S. aureus 5247 Partial synergy Draper et al., 2013
Polymyxin E S. aureus 5247 Indifference Draper et al., 2013
Suicin 3908 Amoxicillin or penicillin S. suis Additive effects Vaillancourt et al., 2015
Thuricin CD Ramoplanin C. difficile Partial synergy/additive against 4/13 strains Mathur et al., 2013
Metronidazole C. difficile Indifference against 13/13 strains Mathur et al., 2013
Vancomycin C. difficile Partial synergy/additive against 2/13 strains Mathur et al., 2013
Subtilosin A Clindamycin phosphate or
metronidazole
G. vaginalis Synergy Cavera et al., 2015
Lauramide arginate or Ester
poly-lysine
G. vaginalis Bliss synergy Cavera et al., 2015
Subtilosin Lauric arginate, ǫ-poly-L-lysine,
glycerol monolaurate
G. vaginalis Synergy Noll et al., 2012
PsVP-10 Triclosan S. mutans and
S. sobrinus
Partial Synergy Lobos et al., 2009
Chlorhexidine S. mutans and
S. sobrinus
Synergy Lobos et al., 2009
Plantaricin E,F,J,K Several antibiotics Candida
albicans
Synergy Sharma and Srivastava,
2014
Durancin 61A Reuterin C. difficile FIC values of 0.2 against C. difficile Hanchi et al., 2017
Vancomycin MRSA FIC values of 0.3 against S. aureus ATCC 700699 Hanchi et al., 2017
study, the antimicrobial activity of nisin Z was potentiated
when combined with thymol at sub-inhibitory concentrations,
against the target strain L. monocytogenes ATCC7644 (Ettayebi
et al., 2000). Significantly, the study showed that 40 IU/ml nisin
combined with 0.02% thymol was more effective at inhibiting
ATCC7644 than either of the antimicrobials used on their own.
A combination of this nature may also preclude the emergence of
bacterial sub-populations displaying resistance to the lantibiotic
(Ettayebi et al., 2000). Another study investigated the effects of
combining nisin with carvacrol or mountain savory essential oils
on the viability of target L. monocytogenes strains subsequent to
γ-irradiation. There was an increase in the relative sensitivity
of L. monocytogenes to γ-irradation by a factor of 6.31 when
nisin and mountain savory essential oils were combined and a
corresponding increase in sensitivity by a factor of 4.19 with
nisin-carvacrol combinations (Ndoti-Nembe et al., 2013).
With regards to combinations of bacteriocins with
preservatives, a study reported that combinations of nisin-
potassium sorbate-ethylene diamine tetraacetic acid (EDTA),
as well as combinations of nisin-sodium-diacetate-EDTA were
effective at reducing the numbers of L. monocytogenes on shrimp
inoculated with the pathogen (Wan Norhana et al., 2012).
Synergistic interactions between nisin and low concentrations
of EDTA in targeting L. monocytogenes were also described in a
study by Branen and Davidson. In addition, the authors showed
that the antimicrobial activity of nisin against L. monocytogenes
was potentiated in the presence of lactoferrin in the same
study (Branen and Davidson, 2004). Combinations of 10 IU/ml
nisin with 250 µg/ml lactoferrin were also shown to perform
synergistically to inhibit L. monocytogenes in a separate study,
similar to Branen and Davidson’s findings (Murdock et al.,
2007).
With respect to other classes of bacteriocins, Grande and co-
workers reported synergistic effects when the class IIc bacteriocin
enterocin AS-48 was combined with the phenolic compound
carvacrol (Grande et al., 2007). The authors conducted a
food trial with vegetable sauces whereby they investigated the
efficacy of AS-48 both independently and when combined with
phenolic substances with a view to inhibiting S. aureus. The
activity of AS-48 was significantly enhanced against S. aureus,
when combined with eugenol, geraniol, terpineol, carvacrol,
hydrocinnamic acid, caffeic acid, citral and p-coumaric acid. The
levels of the pathogen were decreased to less than detectable
levels when 80 µg/ml of AS-48 was mixed with 126 nM carvacrol
or 20 mM hydrocinnamic acid, in carbonara sauce kept at
22◦C. Overall, the degree of synergy obtained depended on
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TABLE 2 | Bacteriocins in combination with other antimicrobials/stressors against biofilms.
Bacteriocin Antimicrobial/Stressor Target biofilm Effect References
Nisin Glu, Asp, Cys S. mutans Improved potency of nisin against biofilms Tong et al., 2014b
Sodium fluoride S. mutans Synergy Tong et al., 2011
Doxycycline E. faecalis Inhibition of biofilms Tong et al., 2013
Several antibiotics MRSA
ATCC43300
Synergy in preventing the formation of biofilms Mataraci and Dosler, 2012
Ciprofloxacin or daptomycin MRSA Decrease in MRSA CFU counts by 3 logs Dosler and Mataraci, 2013
Lysostaphin S. aureus Pre-formed biofilm reduced by >50% for 8 strains Ceotto-Vigoder et al., 2016
Polymyxin P. aeruginosa Reduced concentrations of polymyxins needed to
inhibit biofilm formation
Field et al., 2016b
Nisin M21V Penicillin S. aureus SA113 Biofilm inhibited Field et al., 2016a
Nisin I4V Chloramphenicol S. pseudintermedius
DSM21284
Biofilm inhibited Field et al., 2016a
Nisin M21A Citric acid, cinnamaldehyde L.monocytogenes L. monocytogenes biofilm inhibited Smith et al., 2016
Subtilosin Lauramide arginine ethyl ester
(LAE)
G. vaginalis Effective at inhibiting biofilm Algburi et al., 2015.
Enterocin AS-48 Triclosan, benzalkonium chloride,
PHMG
MRSA Effective when biocides were combined with
50µg/ml AS-48
Caballero Gómez et al.,
2013
Enterocin B3A-B3B Nisin L.monocytogenes MIC needed to disrupt biofilm reduced Al-Seraih et al., 2017
the concentration of the antimicrobials and also the type of
sauce used (Grande et al., 2007). Enterocin AS-48 was also
shown to interact in a synergistic manner with lactic acid,
p-hydroxybenzoic methylester acid (PHBME) and citric acid
in a separate study (Antonio et al., 2009). In salads spiked
with L. monocytogenes, the application of 30 µg/g of AS-48
in combination with PHBME, Nisaplin or lactic acid led to
a significant reduction in L. monocytogenes numbers (Antonio
et al., 2009). Amrouche and co-workers showed that the
sactibiotic bacteriocin subtlosin was effective at inhibiting L.
monocytogenes Scott A and NR30 when combined with ε-poly-
L-lysine, zinc lactate or with curcumin (Amrouche et al., 2010).
The strain L. monocytogenes Scott Awas originally implicated in a
listeriosis outbreak inMassachusetts in 1983 (Fleming et al., 1985;
Briers et al., 2011) while the strain NR-30 has been reported to
display resistance to nisin (Mazzotta andMontville, 1997). Partial
synergy against L. monocytogenes Scott A was apparent when
subtilosin was used in conjunction with an encapsulated form of
curcumin in the study by Amrouche et al., while subtilosin-zinc
lactate combinations also exhibited synergy against both NR30
and Scott A. However, when combined with non-encapsulated
poly-L-lysine or curcumin, subtilosin displayed merely additive
effects against the two L. monocytogenes strains (Amrouche et al.,
2010). Finally, a separate study reported that the combination
of a cell-bound bacteriocin produced by Lactobacillus curvatus
CWBI-B28 with savory essential oil or oregano was effective
at reducing L. monocytogenes to below detectable levels in
pork meat spiked with the pathogen, after a week of storage
(Ghalfi et al., 2007). The oregano essential oil combined with
the cell-bound bacteriocin was still effective after 3 weeks of
storage, whereas all other combinations led to an increase in L.
monocytogenes levels after the same duration of time. Overall,
this cell-bound bacteriocin combined with savory essential oil
was found to retard the growth of L. monocytogenes by 2 weeks,
relative to the use of the cell-bound bacteriocin on its own (Ghalfi
et al., 2007).
L. monocytogenes has the ability to form biofilms in
addition to growing in a planktonic state, and a recent study
demonstrated the effectiveness of the bioengineered derivative of
nisin, M21A, in combination with natural food-grade additives
(cinnamaldehyde and citric acid) in targeting biofilms of strain
F6854 (Smith et al., 2016). This strain has been associated
with contaminated turkey frankfurters (Nelson et al., 2004).
The study by Smith et al., showed that the bioengineered nisin
derivative M21A (0.1 µg/ml) was more effective at inhibiting
F6954 biofilms than wild-type nisin, when combined with
citric acid (175 µg/ml) or cinnamaldehyde (35 µg/ml) (Smith
et al., 2016). A separate study recently reported that the class
IIb bacteriocin, enterocin B3A-B3B, was effective when used
in combination with nisin at decreasing the MIC needed to
disrupt the growth of L. monocytogenes in either a planktonic
state or when present as a biofilm (Al-Seraih et al., 2017).
Finally, the cell-free supernatant (CFS) containing a bacteriocin
from Lb. curvatus ET31 was tested in combination with EDTA
and the investigators noted that while the bacteriocin and the
EDTA independently were ineffective against biofilms which had
already formed, the CFS combined with EDTA was effective
at reducing the viability of L. monocytogenes biofilms which
had already formed, whilst not fully eliminating the biofilms
(Camargo et al., 2016).
Bacteriocins in Combination with Other
Stressors against Gram Negative
Food-Borne Pathogens
Gram negative pathogens in particular have proven to be more
problematic to tackle using bacteriocins than Gram positive
pathogens primarily because of the outer membrane present
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in Gram negatives that limits access to the cell membrane.
Importantly however, the bioengineered nisin variants S29A
and S29G have been shown to display activity against Gram
negatives (Field et al., 2012). While nisin A has been
shown to be effective against Gram negatives when used in
combination with chelating agents such as EDTA, perhaps a
more attractive option is combining nisin with natural phenolic
compounds such as thymol and carvacrol, which facilitate the
permeabilization/disruption of the membrane (Stevens et al.,
1991; Helander et al., 1998). However, as concentrations of
essential oils which are needed to have antimicrobial activity
can compromise the organoleptic qualities of foods, their use
as preservatives in high concentrations have been rather limited
thus far.
Nonetheless, a recent study utilized nisin A, and its
bioengineered derivatives nisin S29A and nisin M21V
independently and in combination with the essential oils
carvacrol, trans-cinnamaldehyde, thymol, as well as the
preservative citric acid, to evaluate the efficacy of such
combinations against the Gram negative food-borne pathogens
Escherichia coli O157: H7 and Cronobacter sakazakii (Campion
et al., 2017). E. coliO157: H7 is an enterohaemorrhagic strain and
has been associated with outbreaks in the US, Canada, UK and
Japan (Besser et al., 1993; Bach et al., 2002; Vidovic and Korber,
2016). C. sakazakii has been associated with contaminated infant
milk formula and is implicated in cases of enteritis, meningitis
and septicaemia (Gurtler et al., 2005; Drudy et al., 2006; Iversen
and Forsythe, 2007; Yan et al., 2012). Campion et al., noted that
extended lag phases of C. sakazakii and O157: H7 were apparent
when 30 µM of the bioengineered nisin variants were combined
with 0.035% trans-cinnamaldehyde, 0.03% carvacrol and 0.015%
thymol, when compared to corresponding combinations of nisin
A-essential oils. In addition, a 4-log reduction of C. sakazakii and
a 3-log reduction in viable counts of O157: H7 was particular
noteworthy when 60 µM of the nisin variants were combined
with 0.03% carvacrol, in comparison to corresponding nisin
A-carvacrol combinations (Figure 1D). Importantly, the study
also showed that when stored at room temperature, sub-lethal
concentrations of nisin variants in combination with carvacrol
were successful in fully inactivating O157: H7 in apple juice,
again when compared to nisin A-carvacrol combinations.
Similarly, the commercial product Nisaplin at concentrations
of 10 mg/ml, in combination with 30 mM citric acid, elicited
>3 log decreases in C. sakazakii viable counts in infant formula
after 3 h of incubation (Campion et al., 2017). The increased
stability of nisin at lower pH conditions compounded by the
ameliorated diffusion properties of essential oils in acidic
conditions could explain the effective combinations in low-pH
drinks such as apple juice (Delves-Broughton, 1990; Burt,
2004; Campion et al., 2017). As thymol and carvacrol disrupt
Gram negative outer membranes (which renders them more
sensitive to nisin), while trans-cinnamaldehyde disrupts the
transmembrane ATPase, combinations of such oils with nisin
may prove to be the most effective option to control Gram
negative food-borne pathogens (Helander et al., 1998; Gill and
Holley, 2006a,b).
With regards to other studies investigating bacteriocin synergy
against Gram negative food-borne pathogens, Moon et al.,
reported that a bacteriocin 4.5 kDa in size from Pediococcus
acidilactici K10 in combination with the organic acids lactic acid,
succinic acid and acetic acid interacted synergistically against
E. coli O157: H7 both in vitro and in situ. This bacteriocin
from P. acidilactici K10 in combination with 0.35% lactic acid
or 0.25% acetic acid was evaluated in a ground beef sample at
4◦C and it was noteworthy that a 2.8-log reduction of O157:
H7 was observed with lactic acid combinations (Moon et al.,
2002). Thus, P. acidilactici and organic acid combinations may
have potential as food bio-preservatives. Branen and Davidson
showed the efficacy of nisin combined with EDTA against
enterohaemorrhagic E. coli strains (Branen and Davidson, 2004)
while a separate study demonstrated the efficacy of 250 IU/ml of
nisin combined with 500 µg/ml lactoferrin at preventing E. coli
O157: H7 growth (Murdock et al., 2007). Finally, Ananou et al.,
observed synergistic effects when enterocin AS-48 was combined
with agents that disrupted the outer membrane of a pathogenic
E. coli O157: H7 isolate (Ananou et al., 2005).
A summary of studies involving bacteriocins in combination
with various stressors with a view to targeting food-borne
pathogens is found in Table 3.
Bacteriocins in Combination with
Antibiotics against Food-Borne Pathogens
While antibiotics are unlikely to be used in foods, several studies
have nonetheless investigated their efficacies in combination
with bacteriocins against food-borne pathogens in laboratory
conditions. Studies of this nature can be useful with regards
to providing insights into the mechanisms of synergistic
interactions, especially when bacteriocins are combined with
antibiotics with known modes of action. Bacillus cereus is an
important food-borne pathogen and several strains have the
ability to cause food poisoning, often resulting in vomiting
and diarrhea (Schoeni and Wong, 2005). In a relatively recent
study, it was shown that the two-component lantibiotic, lacticin
3147, interacted synergistically with the antibiotic polymyxin B
against B. cereus 8079 and B. cereus 5247 (Draper et al., 2013).
Interestingly however, lacticin 3147-polymyxin E combinations
resulted in indifferent (1.0 < FIC < 2.0) and antagonistic effects
(FIC > 2.0), in contrast to the above-mentioned synergistic
interactions with polymyxin B against the same targets, showing
that a single amino acid change in the polymyxin backbone
can lead to profound differences in terms of interactions with
lacticin 3147 against specific target strains. The lantibiotic
nisin and class IIa bacteriocin, pediocin PA-1, have also
been combined with the antibiotic polymyxin E to target L.
monocytogenes and E. coli isolates which had exhibited resistance
to pediocin and polymyxin E respectively (Naghmouchi et al.,
2011). Polymyxin and nisin combinations at concentrations
of 0.6 µg/ml and 15.6 µg/ml; 4.7 µg/ml and 62.5 µg/ml;
and 9.3 µg/ml and 32 µg/ml, respectively, resulted in the
inhibition of polymyxin-resistant E. coli, pediocin PA-1-resistant
L. monocytogenes and nisin-resistant L. monocytogenes variants
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TABLE 3 | Bacteriocins in combination with naturally-derived compounds against food-borne pathogens.
Bacteriocin Antimicrobial/Stressor Target Effect Reference
Nisin Green tea extract or grape seed extract L. monocytogenes Decrease in Listeria levels,
compromised cell membrane and
condensed cytoplasm
Sivarooban et al., 2008
Carvacrol or mountain savory essential
oils
L. monocytogenes Increased sensitivity to γ-irradiation Ndoti-Nembe et al., 2013
Cefotaxime or ceftriaxone Salmonella
Typhimurium
Synergy Singh et al., 2013
EDTA Salmonella
Typhimurium
Additive Singh et al., 2013
Pediocin PA1 E. coli, L.
monocytogenes
Synergy against L. monocytogenes;
ineffective against E. coli
Naghmouchi et al., 2011
Nisin Z Thymol L. monocytogenes
and B. cereus
Dose of nisin Z required reduced Ettayebi et al., 2000
Nisin V Carvacrol, trans-cinnamadehyde or
thymol
L. monocytogenes Extended log phase Field et al., 2015
Nisin S29A or M21V Carvacrol, trans-cinnamadehyde or
thymol
E. coli O157: H7
and C. sakazakii
Extended lag phase of strains. Viable
counts of strains decreased with
carvacrol combinations. Also, O157:
H7 inactivated in apple juice trial with
carvacrol combinations
Campion et al., 2017
Subtilosin Encapsulated curcumin L. monocytogenes
Scott A
Partial synergy Amrouche et al., 2010
Zinc lactate L. monocytogenes
Scott A and NR30
Synergy Amrouche et al., 2010
Non-encapsulated ε-poly-L-lysine,
curcumin
L. monocytogenes
Scott A and NR30
Additive Amrouche et al., 2010
Enterocin AS-48 Carvacrol or hydrocinnamic acid S. aureus Synergy Grande et al., 2007
Eugenol, geraniol, terpineol, carvacrol,
hydrocinnamic acid, caffeic acid, citral
and p-coumaric acid
S. aureus Enhanced activity of enterocin As-48 Grande et al., 2007
Lactic acid, PHBME or citric acid L. monocytogenes Synergy Antonio et al., 2009
Pediocin PA1 Polymyxin E L. monocytogenes Reduced growth of L. monocytogenes
in log and stationary phases
Naghmouchi et al., 2011
Bacteriocin from
Lb. curvatus
CWBI-B28
Savory essential oil, oregano L. monocytogenes Growth of L. monocytogenes retarded
by 2 weeks
Ghalfi et al., 2007
Bacteriocin from
P. acidilactici K10
Lactic acid, succinic acid, aceric acid E. coli O157: H7 Synergy in vitro and in situ Moon et al., 2002
by 74, 97, and 94% respectively, relative to the controls.
While nisin A and pediocin PA-1 combinations were synergistic
against L. monocytogenes and its resistant variants, they were
ineffective against E. coli or its resistant variants. Nonetheless,
nisin-polymyxin combinations at concentrations of 7.8 µg/ml
and 0.3 µg/ml, respectively, and polymyxin independently at
a concentration of 0.21 µg/ml decreased the growth of log
phase E. coli cells by approximately 94 and 31% respectively.
Pediocin PA-1-polymyxin E combinations at concentrations of
25 µg/ml and 4.7 µg/ml, respectively, reduced the growth
of L. monocytogenes in the exponential and stationary phases
by 90% and 78%, respectively. Thus, the study indicated that
resistant L. monocytogenes and E. coli isolates can be managed
by using combinations of nisin/polymyxin E or pediocin PA-
1/polymyxin E respectively (Naghmouchi et al., 2011). The same
group also evaluated the activity of colistin in combination with
pediocin PA-1/AcH or nisin with a view to targeting E. coliO157:
H7, Yersinia enterocolitica ATCC 9610, P. aeruginosa ATCC
27853 and Salmonella choleraesuis ATCC 14028. Significantly,
1.56 µg/ml of pediocin PA-1/AcH or 1.7 µg/ml of nisin
in combination with colistin elicited a marked reduction in
the concentration of colistin needed to inhibit O157: H7
(Naghmouchi et al., 2013).
With respect to studies involving other Gram negative
food-borne pathogens, lacticin 3147 was reported to exhibit
synergy when combined with polymyxin B against C. sakazakii
DPC6440 with FIC values of 0.25 (Draper et al., 2013). The
lantibiotic also exhibited synergistic activity against the same
strain when combined with polymyxin E with corresponding
FIC values of 0.062 against DPC6440. Interestingly however,
indifferent and antagonistic effects were obtained when lacticin
3147 was combined with polymyxin B or polymyxin E against
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the target strains Salmonella Typhimurium UK1 and LT2, with
FIC values greater than 1.125 in all cases (Draper et al., 2013).
A separate study by Rishi and co-workers demonstrated the
efficacy of β-lactam antibiotics combined with nisin with a
view to inhibiting the food-borne pathogen Salmonella enterica
serovar Typhi (Rishi et al., 2014). Nisin-β-lactam synergistic
combinations were assessed by conducting FIC and time-kill
assays and with the exception of three strains, synergy was
observed with all combinations against the clinical Salmonella
strains in the in vitro study by Rishi and co-workers with nisin-
cefotaxime and nisin-ceftriaxone proving to be the most effective
combinations (Rishi et al., 2014). Singh et al., in a similar
study, also evaluated the effectiveness of nisin in combination
with standard antibiotics against multi-drug resistant strains of
Salmonella and any such synergistic interactions were evaluated
by FIC determinations using the checkerboard assay as well
as time-kill assays and radial diffusion assays (Singh et al.,
2013). Furthermore, scanning electron microscopy (SEM) and
mouse trials assessing the combinatorial interactions were also
conducted to validate synergistic effects observed with in vitro
assays. Decreases in the numbers of Salmonella in various
organs of infected mice were observed as a consequence of
the antimicrobial combination. Using FIC values and time-
kill assays, nisin-cefotaxime and nisin-ceftriaxone combinations
yielded synergistic effects whereas nisin-EDTA and nisin-
ampicillin combinations yielded additive effects against serovar
Typhimurium. Significant alterations in the outer membrane of
the target cells, elicited by the antimicrobial combinations were
apparent and bacteriocin-β-lactam combinations caused greater
log decreases of Salmonella in the spleen, intestine and liver of
mice, relative to treatment with the antimicrobials independently
(Singh et al., 2013). More specifically, the combination of nisin
(at concentrations of 25 mg/Kg body weight and 50 mg/Kg
body weight) with ceftriaxone (also at concentrations of 25
mg/Kg and 50 mg/Kg) resulted in 2.83, 3.11, 2.6, and 3.1-
log decreases in Salmonella respectively in the spleen. Identical
concentrations of nisin and cefotaxime were also combined,
resulting in 2.06, 2.49, 2.11, and 2.44-log decreases respectively
in the spleen as well. In contrast, 25 mg/Kg nisin and 50
mg/Kg nisin administered independently resulted in a mere 0.16
and 0.3-log decrease respectively in Salmonella in the spleen.
Similarly, combinations of nisin (25 mg/Kg body weight and
50 mg/Kg body weight) combined with identical concentrations
of ceftriaxone proved to be effective, resulting in decreases
in Salmonella in the liver ranging from 2.75 to 3.5-log units.
Corresponding combinations of nisin and cefotaxime resulted in
reductions in Salmonella in the liver ranging from 2.27 to 3.26-
log units. These values were higher than the 0.42 to 0.67-log unit
reductions achieved by nisin independently. Following on from
this study, the same group attempted to elucidate the mechanism
of these synergistic interactions (Singh et al., 2014). Essentially,
the ability of nisin and the β-lactams to target the cell membrane
was evaluated by conducting membrane permeabilizing assays
in combination with pulse labeling techniques. The results
showed that the bacteriocin-β-lactam combination affected
membrane permeability, as confirmed by the uptake of 1-N-
phenylnapthylamine (NPN) by the treated cells. This uptake
of NPN as a consequence of membrane permeabilization, as
well as interference with DNA, RNA and protein synthesis was
dependent on both the dose of the antimicrobials, as well as
the duration of exposure to the antimicrobials in combination.
Significantly, results of in vivo assays involving mouse trials
corroborated synergistic effects seen in in vitro assays in the study
(Singh et al., 2014). Thus, nisin-cefotaxime and nisin-ceftriaxone
synergistic effects against Salmonella were predominantly due
to permeabilization of the membrane, as well as DNA, RNA,
protein synthesis inhibition, and immune-modulatory activity
(Singh et al., 2014).
OTHER TYPES OF EFFECTIVE
INTERACTIONS AGAINST PATHOGENS
INVOLVING BACTERIOCINS
A potential strategy with a view to combating recalcitrance
to traditional antibiotics may be to combine bacteriocins with
phages/endolysins and some studies have already investigated
such prospects. For instance, a recent study evaluated the efficacy
of combinations of the class II bacteriocin coagulin C23 with
listeriaphages against L. monocytogenes and found that they
act in a synergistic manner against the food-borne pathogen
(Rodríguez-Rubio et al., 2015). More specifically, coagulin C23
was combined with the phages FWLLm1 or FWLLm3 and
synergistic effects were apparent when the two antimicrobials
were mixed in sub-inhibitory concentrations. Encouragingly, L.
monocytogenes 2000/47 levels were lower than 10 CFU/ml after
96 h of storage at 4◦C, when the bacteriocin was combined with
the phage FWLLm1. However, the combination of coagulin C23
and FWLLm3 was not effective at inhibiting L. monocytogenes
2000/47 and this could be attributed to the emergence of mutants
resistant to coagulin C23 and FWLLm3. Significantly, the authors
in the study concluded that the rate of development of resistance
was higher when the antimicrobials were used independently,
relative to the combination of the two antimicrobials together.
This phenomenon of delayed resistance development could
explain the synergistic effects observed in the study (Rodríguez-
Rubio et al., 2015).
Synergy was also observed when nisin was combined with the
S. aureus lytic phages phiφ35 and φ88 in another study (Martínez
et al., 2008). Unfortunately, the use of this combination as a viable
therapeutic option has been hindered due to the emergence of
resistance to the two phages employed and adaptation to the
lantibiotic nisin. With regards to other studies relating to phages
combined with bacteriocin-like agents with a view to targeting
S. aureus, the bacteriolysin lysostaphin exhibited synergistic
effects in combination with the two endolysins (LysK) against
MRSA (Dajcs et al., 2002; O’Flaherty et al., 2005; Becker et al.,
2008). A deeper understanding of the mechanisms of synergistic
interactions between bacteriocins and endolysins is essential if
such an interaction is to be used in food/clinical settings. In the
case of lysostaphin-LysK synergy, it may be that LysK by virtue
of the fact that it has two lytic domains, has the ability to further
potentiate the lytic nature of lysostaphin, which merely possesses
one lytic domain (Becker et al., 2008). Finally, a study by Garcia
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et al., also reported synergistic interactions between nisin and the
phage endolysin LysH5 (García et al., 2010). The activity of LysH5
may be enhanced by the ability of nisin to permeabilize the cell
membrane of target S. aureus strains (Nascimento et al., 2008;
Obeso et al., 2008).
THE USE OF MATHEMATICAL MODELS TO
ASSESS ANTIMICROBIAL SYNERGY AND
PREDICT RESISTANCE DEVELOPMENT
While synergistic antimicrobial interactions are likely to be
beneficial in clinical applications, the emergence of multi-
drug resistance arising from such interactions remains unclear.
Recently, mathematical modeling has enhanced the predictive
capabilities of such antimicrobial interactions with regards to
development of resistance (Ankomah and Levin, 2012; Chen
et al., 2015). Indeed, Torella et al., addressed this phenomenon
by optimizing a mathematical model to study infections in vivo
and found that there were two opposite effects of synergy:
(i) the synergistic interaction results in more rapid clearance
of the infection and consequently fewer opportunities for
the development of resistant derivatives/mutants and (ii) the
selection of resistant isolates/derivatives is favored over wild-
type cells associated with synergistic interactions (Torella et al.,
2010). The authors found that when resources are abundant, the
synergistic effects are more potent at eliminating the infection
but conversely, when resources are limited, the potential for
development of multi-drug resistance also increases. Above
a certain critical level of drug interaction, the potential for
emergence of multi-drug resistance is enhanced. Interestingly,
the study suggested that to dampen down the emergence
of multi-drug resistance, antimicrobial antagonism may on
occasions actually be better than antimicrobial synergy (Torella
et al., 2010).
In a similar study, Landersdorfer et al. devised a model for
evaluating the synergistic interactions of antibiotic combinations
using a sequential dosing design (Landersdorfer et al., 2013).
The authors used nisin in combination with either linezolid
or amikacin for the study. Sequential, as well as simultaneous,
administration of the antimicrobials enabled the evaluation
of the efficacy of linezolid or amikacin against populations
of cells which were nisin-resistant or nisin-intermediate cells.
Landersdorfer et al. used the software NONMEM and S-ADAPT
to model the synergistic interactions. The study found that while
bacterial replication was inhibited by linezolid in populations less
sensitive to nisin, this population of cells was not efficiently killed.
The combination of amikacin with the lantibiotic nisin resulted
in sub-population synergy. Such models of simultaneous or
sequential antimicrobial dosing models may enable scientists to
devise effective antimicrobial combination strategies for clinical
applications (Landersdorfer et al., 2013).
In a landmark study, the concept of “the smile-frown
transition” with respect to antimicrobial synergy was introduced
(Pena-Miller et al., 2013). The authors used mathematical
modeling, whole genome sequencing, genetic manipulation
of resistance mechanisms and evolution experiments to
demonstrate that synergistic antimicrobial combinations can be
ineffective unless the first round of treatment results in bacterial
clearance. It was suggested that the potency of antimicrobial
synergy decreases concurrently with the emergence of drug-
resistant bacteria. Evolution experiments exhibited that the
efficacy of the antibiotics used exponentially decreased over
a 5 day period. The authors also found that the replication
of drug-resistant bacteria was fastest when the drug-sensitive
counterparts were killed by aggressive treatment strategies (Pena-
Miller et al., 2013). The initial synergistic interaction created
a selective pressure for the emergence of resistance causing
antagonistic effects after day 1 of the 5-day experiment. The
authors dubbed this phenomenon “the smile-frown transition.”
Genome sequencing in the study showed that emergence of
resistance to the antibiotics may be due to the amplification
of genes involved in drug-resistance mechanisms such as the
acrAB eﬄux operon (Pena-Miller et al., 2013). The deletion of
this acrAB operon precluded the transition from antimicrobial
synergy to antimicrobial antagonism within 5 days of the
evolution experiments. Thus, evidence such as that outlined
by Pena-Miller implies that super-inhibitory concentrations of
the two antimicrobials in combination may need to be used
until the pathogen is fully cleared. Conversely, in the presence
of sub-inhibitory concentrations of the two antimicrobials, the
“smile-frown transition” is likely to take precedence (Pena-Miller
et al., 2013).
CONCLUSIONS
The 20th century was the golden era for the discovery of
novel antibiotics and successful infection control strategies.
However, the over-prescription of broad-spectrum antibiotics
by clinicians worldwide in combination with overuse in animal
applications has triggered an increase in antibiotic resistance
and, in addition, has contributed to nosocomial infections
such as C. difficile infection (CDI), due to perturbations of
the gut microbiota. Furthermore, the broad-spectrum nature
of several antibiotics as well as the negative links associated
with the causation of autoimmune and atopic diseases with
certain antibiotics renders them unattractive options (Blaser,
2011; Willing et al., 2011). The over-exposure to antibiotics
in the environment, healthcare settings and in agriculture has
contributed to this problem. Furthermore, the increase in global
travel, compounded by poor infection control standards, has
also exacerbated the crisis (Holmes et al., 2016). In particular,
in hospital settings, the dissemination of antibiotic-resistant
pathogens, especially in immunosuppressed patients is a cause
for concern. A thorough understanding of the mechanisms of
antibiotic resistance is urgently warranted to mitigate this global
concern. Alternative therapeutic options, including bacteriocins
used either independently or in combination with other
stressors must also be thoroughly explored. Amongst the key
advantages of bacteriocins include their ribosomally-synthesized
nature, which renders them amenable to bioengineering
strategies. Such bioengineered variants may possess enhanced
bioactivity against certain clinical/food-borne pathogens or food
Frontiers in Microbiology | www.frontiersin.org 12 June 2017 | Volume 8 | Article 1205
Mathur et al. Effective Bacteriocin-Antimicrobial Combinations
spoilage organisms, as well as potentially possessing ameliorated
physicochemical properties such as improved solubility, protease
resistance and pH tolerance, further augmenting their value
and effectiveness as antimicrobials. Other potential advantages
of using bacteriocins include their high potency against target
strains, their stability and their low toxicity. A potential
disadvantage is that oral ingestion is complicated due to their
proteolytic digestion in the gut. However, this may be overcome
by advances in encapsulation technologies. Another means
to circumvent proteolytic breakdown is to administer them
parenterally for systemic applications.
Although there have already been studies conducted which
have revealed potentially promising synergistic interactions
between bacteriocins and other stressors, it must be highlighted
that, since there are a large number of bacteriocin-antimicrobial
combinations that have yet to be investigated, there could still
be very useful combinations against targeted pathogens which
are currently untapped. Thus, far, a precise understanding of
the mechanism of synergistic interactions of antimicrobial
combinations has hindered the progress of alternative
therapeutic options of bacteriocin-antimicrobial combinations
against target strains, particularly in clinical settings. Indeed,
there has been a general reluctance in resorting to alternative
therapeutic options and changing the status quo in the clinical
arena. Elucidation of the mode of action of these synergistic
interactions using a combination of genomic, transcriptomic and
proteomic tools is likely to expedite the processes involved in
the deployment of these antimicrobial combinations in clinical
and/or food settings.
With respect to the clinical efficacy of bacteriocin-
antimicrobial combinations, the precise nature of
physicochemical interactions, such as hydrophobic-hydrophobic
or cationic-anionic interactions, between a proteinaceous
bacteriocin and an antibiotic are likely to be important
considerations when optimizing effective combinatorial
therapy for use in vivo. In this regard, it may also be the case
that combinations of two bacteriocins that are of a similar
molecular weight may be more effective in vivo than combining
a high molecular weight bacteriocin with a low molecular
weight antibiotic. In addition, the pharmacodynamic and
pharmacokinetic traits of a bacteriocin are likely to be critical
factors determining its success as a potential therapeutic agent
in vivo. This becomes even more relevant when combined with
antibiotics as physicochemical interactions of the bacteriocin
with the antibiotic can interfere with the pharmacodynamic
properties of both antimicrobials. With respect to the
pharmacokinetic properties of bacteriocins in combination
with antibiotics, optimization of the route of administration
of the two antimicrobials to the localized site of infection is
likely to be an important step in determining the success of the
treatment. Indeed, localized cutaneous, intravaginal or inhaled
routes of administration of bacteriocins may be effective due
to the relatively low absorption rates, minimizing potentially
undesired systemic side effects (Ghobrial et al., 2009, 2010a;
van Heel et al., 2011). However, this may be complicated in the
presence of an antibiotic used in combination. With respect
to systemic applications however, the lantibiotic group of
bacteriocins in particular could prove to be less efficacious due
to their propensity to bind blood components (Ghobrial et al.,
2010b). Thus, the distribution and consequent bioavailability of
such bacteriocins in the desired target site can unfortunately be
significantly attenuated. Aside from reducing the bioavailability,
the binding of bacteriocins to plasma proteins can also reduce
the specific activity of the bacteriocin against a target strain
by potentially hindering access of the bacteriocin to its target
receptor (Ghobrial et al., 2010b). This problem can be further
exacerbated due to the instability of certain lantibiotics under
physiological pH conditions. However, bioengineering strategies
with a view to seeking derivatives with enhanced stability has the
potential to somewhat mitigate this issue (Rollema et al., 1995;
Yuan et al., 2004). It must also be highlighted that differences in
the rates of metabolism and excretion of bacteriocins combined
with antibiotics are likely to exist between animals and humans,
and the half-life of each of the antimicrobials can have an impact
on the propensity for development of resistance. In addition,
further insights with respect to the effects of such antimicrobial
combinations on eukaryotic cells are also essential in order to
prevent any undesired side effects. Encouragingly, the evidence
accumulated thus far has shown that bacteriocins in general
tend to display low toxicity rates against epithelial cells and with
the exception of cytolysin, generally tend to exhibit extremely
low levels of hemolysis (Cox et al., 2005; Maher and McClean,
2006; Aranha et al., 2008). However, all these factors above can
be further complicated and clinical outcomes difficult to predict
when bacteriocins are combined with other antimicrobials.
Overall, optimization of effective therapeutic concentrations of
bacteriocins, either independently or in combination with other
antimicrobials can only truly be achieved with the availability of
more data concerning the pharmacokinetic properties of each of
the antimicrobials in question. Therefore, a complex interplay of
factors is bound to be crucial in governing the clinical efficacy of
such potential combinatorial therapeutic options.
While bacteriocins interacting synergistically with other
antimicrobials and stressors could have great potential in clinical
and food settings, one must be aware that unfortunately,
bacteriocins are by no means a “magic bullet” and are not exempt
from development of resistance (Modi et al., 2000; Draper et al.,
2015). Indeed, several different mechanisms of resistance to the
lantibiotic subclass of bacteriocins have been described, which
include cell-envelope altering mechanisms utilized by bacteria
such as DltA or MprF (Peschel et al., 1999; Poyart et al., 2001;
Abachin et al., 2002; Kovacs et al., 2006; Khattar et al., 2009;
McBride and Sonenshein, 2011a,b), two component systems
such as CprK in C. difficile (McBride and Sonenshein, 2011a,b;
Suarez et al., 2013) and LisRK in L. monocytogenes (Cotter
et al., 1999; Kallipolitis and Ingmer, 2001), as well as other
mechanisms such as production of nisin resistance proteins
(Chatterjee et al., 2005; O’Driscoll et al., 2006; Khosa et al.,
2013) (for a comprehensive review on lantibiotic resistance,
see Draper et al., 2015). Resistance to the class II group of
bacteriocins have also been described in laboratory conditions
and is likely to be mediated through decreased expression of
Man-PTS receptors (Kjos et al., 2011). Ultimately, greater insights
into the precise mechanisms of development of resistance to
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bacteriocins will facilitate their deployment in both clinical
settings and as preservatives in food, either individually or in
combination with other antimicrobials.
While it is plausible that the combination of two
antimicrobials with two distinct modes of action attenuates
the likelihood of resistance development, the emergence
of sub-populations of target pathogens recalcitrant to both
the bacteriocin as well as the other antimicrobial used in
combination, remains a very realistic worst case scenario. It
is interesting, in this regard, to note that the development
of resistance to bacteriocins over the years has generally
been associated with a slower growth rate and an associated
fitness cost in resistant variants. Even though bacteriocins
have been studied for several decades, the precise mechanisms
of antimicrobial action of several of these peptides are still
unknown. Knowledge of the exact modes of action of such
bacteriocins would potentially help researchers to tailor-make
“designer bacteriocins” which may act synergistically with other
antimicrobials, with a view to targeting specific pathogens.
By doing so, researchers could combine bacteriocins with
certain antimicrobials whose modes of action are already
known, in a target-specific manner. Finally, it must be
highlighted that successful synergistic interactions between
bacteriocins and other antimicrobials in vitro may not
necessarily correlate with clinical efficacy. Nonetheless,
optimization of a variety of complex factors including
the pharmacodynamics/pharmacokinetic properties of the
antimicrobials as well as antimicrobial concentrations and ratios
at which the antimicrobials work in a synergistic fashion can lead
to effective alternative therapeutic options with the ultimate view
to confronting the increasingly worrying problem of antibiotic
resistance.
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